Journal of Biological Chemistry · 2012 · 23 citations · 43 references
Life SciencesBiochemistryMolecular BiologyCell SignalingGene ExpressionSignal TransductionGonadal HormonesGonadal Steroid HormonesHormone ReceptorsHormone SignalingNuclear ReceptorsSteroid Hormone SignalingAndrogen MetabolismAndrogen Receptor ExpressionAndrogen Receptor RegulationAndrogen ReceptorsRecruitment Kinetics
The androgen receptor (AR) has a critical role in the growth and progression of androgen-dependent and castration-resistant prostate cancers. To identify novel inhibitors of AR transactivation that block growth of prostate cancer cells, a luciferase-based high-throughput screen of ∼160,000 small molecules was performed in cells stably expressing AR and a prostate-specific antigen (PSA)-luciferase reporter. CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile) was identified as a small molecule that blocks AR transactivation to a greater extent than other steroid receptors. CPIC inhibited AR-mediated proliferation of androgen-sensitive prostate cancer cell lines, with minimal toxicity in AR-negative cell lines. CPIC treatment also reduced the anchorage-independent growth of LAPC-4 prostate cancer cells. CPIC functioned as a pure antagonist by inhibiting the expression of AR-regulated genes in LAPC-4 cells that express wild-type AR and exhibited weak agonist activity in LNCaP cells that express the mutant AR-T877A. CPIC treatment did not reduce AR levels or alter its nuclear localization. We used chromatin immunoprecipitation to identify the site of action of CPIC. CPIC inhibited recruitment of androgen-bound AR to the PSA promoter and enhancer sites to a greater extent than bicalutamide. CPIC is a new therapeutic inhibitor that targets AR-mediated gene activation with potential to arrest the growth of prostate cancer. Background: Androgen receptor (AR) is a major therapeutic target for inhibiting proliferation of prostate cancer cells. Results: A newly identified AR inhibitor, CPIC, works by reducing AR binding to regulated genes. Conclusion: CPIC has a different mode of action from classical AR antagonists such as bicalutamide. Significance: CPIC has therapeutic potential in the treatment of prostate cancer and is a new tool for studying AR.
43
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science · 2009 · 2.3K citations · Full text
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Yongfeng Shang, Xiao Hu, James DiRenzo et al. · Cell · 2000 · 1.7K citations · Full text
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Howard I. Scher, Tomasz M. Beer, Celestia S. Higano et al. · The Lancet · 2010 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +13